Jessica M. McDaniel, Ph.D.
Affiliations: | 2012 | Biology (Cell Biology, Microbiology, Molecular Biology) | University of South Florida, Tampa, FL, United States |
Area:
Immunology, Oncology, Cell BiologyGoogle:
"Jessica McDaniel"Parents
Sign in to add mentor| P K. Epling-Burnette | grad student | 2012 | University of South Florida | |
| (Lenalidomide targets the T-cell co-stimulatory pathway to mediate immune modulation.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Hesterberg RS, Beatty MS, Han Y, et al. (2020) Cereblon Harnesses Myc-Dependent Bioenergetics and Activity of CD8+ T lymphocytes. Blood |
| Akuffo AA, Alontaga AY, Metcalf R, et al. (2018) Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon. The Journal of Biological Chemistry |
| Wan X, Sato H, Miyaji H, et al. (2013) Fucosyltransferase VII improves the function of selectin ligands on cord blood hematopoietic stem cells. Glycobiology. 23: 1184-91 |
| Padron E, Painter JS, Kunigal S, et al. (2013) GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 121: 5068-77 |
| Epling-Burnette PK, Han Y, Mailloux AW, et al. (2013) Novel Predictor Of Lenalidomide Response In Non-del5q MDS Reveals Linkage To Molecular Mechanism: First Characterization Of T-Cell Function In Cereblon Homozygous Deficient Mice Blood. 122: 748-748 |
| Han Y, Rajadhyaksha AM, Mailloux AW, et al. (2013) Characterization Of RING Finger E3-Ubiquitin Ligase Cereblon In Hematopoietic Regulation Blood. 122: 1207-1207 |
| Epling-Burnette PK, McDaniel J, Wei S, et al. (2012) Emerging immunosuppressive drugs in myelodysplastic syndromes. Expert Opinion On Emerging Drugs. 17: 519-41 |
| McDaniel JM, Pinilla-Ibarz J, Epling-Burnette PK. (2012) Molecular action of lenalidomide in lymphocytes and hematologic malignancies. Advances in Hematology. 2012: 513702 |
| McDaniel JM, Zou JX, Fulp W, et al. (2012) Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation. Leukemia. 26: 1425-9 |
| Padron E, Painter JS, Mailloux AW, et al. (2012) Preclinical Characterization of KB003, a Novel Humaneeredâ„¢ Monoclonal Anti-GM-CSF Antibody, Demonstrates That the GM-CSF Signaling Axis Is a Therapeutic Target in Chronic Myelomonocytic Leukemia (CMML) Blood. 120: 3793-3793 |